{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T05:21:07Z","timestamp":1764480067506,"version":"3.46.0"},"reference-count":143,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>A crucial role of genome instability and telomeric dysfunction was demonstrated in multiple cancers, including multiple myeloma (MM). MM accounts for approximately 10% of all hematologic malignancies and includes asymptomatic pre-malignant monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Due to the highly heterogeneous nature of the disease, there is an ongoing need for precise risk stratification and subsequent development of risk-adapted treatment strategies at every stage of disease and during disease progression. Telomere numbers, intensity, aggregates, and spatial arrangement within the nucleus were identified as prognostic biomarkers. Recent studies demonstrated that the three-dimensional (3D) analysis of key telomeric parameters is a reliable marker of the high risk of relapse in newly diagnosed MM (NDMM) patients and can predict the risk of progression of SMM patients. Telomeric parameters of malignant MM cells from the peripheral blood and bone marrow were similar, suggesting that 3D telomere profiling may assess MRD in liquid biopsies of MM patients. This review focuses on the prognostic value of 3D telomere profiling in MM. 3D spatial telomere analysis may potentially address a critical unmet clinical need in managing MM and, if incorporated into current guidelines, help to accurately predict disease status, progression risk, overall survival, and response to treatment.<\/jats:p>","DOI":"10.3390\/cells14231890","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:56:02Z","timestamp":1764323762000},"page":"1890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma"],"prefix":"10.3390","volume":"14","author":[{"given":"Yulia","family":"Shifrin","sequence":"first","affiliation":[{"name":"Telo Genomics Corp., Toronto, ON M5V 3B1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-2201","authenticated-orcid":false,"given":"Sabine","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Physiology & Pathophysiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","article-title":"Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies","volume":"8","author":"Jafri","year":"2016","journal-title":"Genome Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1073\/pnas.0609410104","article-title":"Telomere dysfunction as a cause of genomic instability in Werner syndrome","volume":"104","author":"Crabbe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1593\/neo.91004","article-title":"Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma","volume":"12","author":"Silva","year":"2010","journal-title":"Neoplasia"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"de Oliveira, F.M., Jamur, V.R., Merfort, L.W., Pozzo, A.R., and Mai, S. (2022). Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10094-5"},{"key":"ref_5","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","unstructured":"Albagoush, S.A., Shumway, C., and Azevedo, A.M. (2025). Multiple Myeloma. StatPearls, StatPearls Publishing."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Abduh, M.S. (2024). An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi J. Biol. Sci., 31.","DOI":"10.1016\/j.sjbs.2023.103920"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clml.2020.01.017","article-title":"Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","volume":"20","author":"Bergstrom","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_10","unstructured":"Kaseb, H., Annamaraju, P., and Babiker, H.M. (2025). Monoclonal Gammopathy of Undetermined Significance. StatPearls, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-010-0047-9","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"5","author":"Kyle","year":"2010","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Kyle","year":"2011","journal-title":"Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-024-00980-5","article-title":"Mode of progression in smoldering multiple myeloma: A study of 406 patients","volume":"14","author":"Abdallah","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.hoc.2023.12.001","article-title":"Smoldering Multiple Myeloma: Observation Versus Control Versus Cure","volume":"38","author":"Rajkumar","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Medina-Herrera, A., Sarasquete, M.E., Jim\u00e9nez, C., Puig, N., and Garc\u00eda-Sanz, R. (2023). Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers, 15.","DOI":"10.3390\/cancers15143687"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Aksenova, A.Y., Zhuk, A.S., Lada, A.G., Zotova, I.V., Stepchenkova, E.I., Kostroma, I.I., Gritsaev, S.V., and Pavlov, Y.I. (2021). Genome Instability in Multiple Myeloma: Facts and Factors. Cancers, 13.","DOI":"10.3390\/cancers13235949"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Maura, F., Bergsagel, P.L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.J., Firestone, R., Braggio, E., and Asmann, Y. (2025). Genomics Define Malignant Transformation in Myeloma Precursor Conditions. J. Clin. Oncol., Jco2501733.","DOI":"10.1016\/S2152-2650(25)03448-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_21","first-page":"283","article-title":"IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc","volume":"224","author":"Bergsagel","year":"1997","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chuang, T.C., Moshir, S., Garini, Y., Chuang, A.Y., Young, I.T., Vermolen, B., van den Doel, R., Mougey, V., Perrin, M., and Braun, M. (2004). The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol., 2.","DOI":"10.1186\/1741-7007-2-12"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1593\/tlo.13613","article-title":"Three-dimensional Nuclear Telomere Organization in Multiple Myeloma","volume":"6","author":"Klewes","year":"2013","journal-title":"Transl. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wark, L., Quon, H., Ong, A., Drachenberg, D., Rangel-Pozzo, A., and Mai, S. (2019). Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy. Cancers, 11.","DOI":"10.3390\/cancers11081165"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cyto.a.20159","article-title":"Characterizing the three-dimensional organization of telomeres","volume":"67","author":"Vermolen","year":"2005","journal-title":"Cytometry A"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/ajh.27364","article-title":"Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma","volume":"99","author":"Kumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e19560","DOI":"10.1200\/JCO.2025.43.16_suppl.e19560","article-title":"Preliminary results of 3D telomeres profiling for myeloma MRD and evaluation of concordance between blood and marrow","volume":"43","author":"Kaedbey","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"223","article-title":"Rise, fall and resurrection of chromosome territories: A historical perspective. Part II. Fall and resurrection of chromosome territories during the 1950s to 1980s. Part III. Chromosome territories and the functional nuclear architecture: Experiments and models from the 1990s to the present","volume":"50","author":"Cremer","year":"2006","journal-title":"Eur. J. Histochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/35066075","article-title":"Chromosome territories, nuclear architecture and gene regulation in mammalian cells","volume":"2","author":"Cremer","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-020-15718-7","article-title":"Super-resolution imaging reveals the evolution of higher-order chromatin folding in early carcinogenesis","volume":"11","author":"Xu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_31","first-page":"1000165","article-title":"Genomic Instability and Cancer","volume":"5","author":"Yao","year":"2014","journal-title":"J. Carcinog. Mutagen."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2174\/1381612827666210426100206","article-title":"Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials","volume":"27","author":"Salmaninejad","year":"2021","journal-title":"Curr Pharm. Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41568-020-00321-1","article-title":"Aneuploidy as a promoter and suppressor of malignant growth","volume":"21","author":"Vasudevan","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","article-title":"Genomic and Functional Approaches to Understanding Cancer Aneuploidy","volume":"33","author":"Taylor","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.trecan.2015.10.007","article-title":"Deciphering the Code of the Cancer Genome: Mechanisms of Chromosome Rearrangement","volume":"1","author":"Willis","year":"2015","journal-title":"Trends Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2016.171","article-title":"Telomeres in cancer: Tumour suppression and genome instability","volume":"18","author":"Maciejowski","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1535-6108(02)00094-6","article-title":"Telomere dysfunction provokes regional amplification and deletion in cancer genomes","volume":"2","author":"Chang","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cell.2010.01.031","article-title":"Persistent telomere damage induces bypass of mitosis and tetraploidy","volume":"141","author":"Davoli","year":"2010","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1101\/sqb.2005.70.032","article-title":"Telomere-related genome instability in cancer","volume":"70","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/jcb.22501","article-title":"Initiation of telomere-mediated chromosomal rearrangements in cancer","volume":"109","author":"Mai","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Harman, A., and Bryan, T.M. (2024). Telomere maintenance and the DNA damage response: A paradoxical alliance. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1472906"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nature05976","article-title":"Replication and protection of telomeres","volume":"447","author":"Verdun","year":"2007","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(00)80760-6","article-title":"Mammalian telomeres end in a large duplex loop","volume":"97","author":"Griffith","year":"1999","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev.genet.41.110306.130350","article-title":"How shelterin protects mammalian telomeres","volume":"42","author":"Palm","year":"2008","journal-title":"Annu. Rev. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cell.2008.11.045","article-title":"Purification of proteins associated with specific genomic Loci","volume":"136","author":"Kingston","year":"2009","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/scientificamerican0296-92","article-title":"Telomeres, telomerase and cancer","volume":"274","author":"Greider","year":"1996","journal-title":"Sci. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.gde.2020.02.007","article-title":"Genetic determinants of telomere length and cancer risk","volume":"60","author":"Nelson","year":"2020","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, C., Chen, X., Li, L., Zhou, Y., Wang, C., and Hou, S. (2015). The Association between Telomere Length and Cancer Prognosis: Evidence from a Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133174"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Srinivas, N., Rachakonda, S., and Kumar, R. (2020). Telomeres and Telomere Length: A General Overview. Cancers, 12.","DOI":"10.3390\/cancers12030558"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dratwa, M., Wysocza\u0144ska, B., \u0141acina, P., Kubik, T., and Bogunia-Kubik, K. (2020). TERT-Regulation and Roles in Cancer Formation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.589929"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhu, X., Han, W., Xue, W., Zou, Y., Xie, C., Du, J., and Jin, G. (2016). The association between telomere length and cancer risk in population studies. Sci. Rep., 6.","DOI":"10.1038\/srep22243"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11684-016-0450-2","article-title":"Association between telomere length and survival in cancer patients: A meta-analysis and review of literature","volume":"10","author":"Xu","year":"2016","journal-title":"Front. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature14513","article-title":"Cell death during crisis is mediated by mitotic telomere deprotection","volume":"522","author":"Hayashi","year":"2015","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cell.2015.11.054","article-title":"Chromothripsis and Kataegis Induced by Telomere Crisis","volume":"163","author":"Maciejowski","year":"2015","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(01)80006-4","article-title":"Telomere shortening and tumor formation by mouse cells lacking telomerase RNA","volume":"91","author":"Blasco","year":"1997","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Holesova, Z., Krasnicanova, L., Saade, R., P\u00f6s, O., Budis, J., Gazdarica, J., Repiska, V., and Szemes, T. (2023). Telomere Length Changes in Cancer: Insights on Carcinogenesis and Potential for Non-Invasive Diagnostic Strategies. Genes, 14.","DOI":"10.3390\/genes14030715"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e29901","DOI":"10.4161\/mco.29901","article-title":"Telomere uncapping at the crossroad between cell cycle arrest and carcinogenesis","volume":"1","author":"Gobbini","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1101\/gad.1029903","article-title":"Telomere-based crisis: Functional differences between telomerase activation and ALT in tumor progression","volume":"17","author":"Chang","year":"2003","journal-title":"Genes Dev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40164-025-00597-9","article-title":"Telomeres, telomerase, and cancer: Mechanisms, biomarkers, and therapeutics","volume":"14","author":"Shou","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Bernal, A., and Tusell, L. (2018). Telomeres: Implications for Cancer Development. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010294"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/35020592","article-title":"Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice","volume":"406","author":"Artandi","year":"2000","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"M\u2019Kacher, R., Cuceu, C., Al Jawhari, M., Morat, L., Frenzel, M., Shim, G., Lenain, A., Hempel, W.M., Junker, S., and Girinsky, T. (2018). The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes. Cancers, 10.","DOI":"10.3390\/cancers10060169"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"De Vitis, M., Berardinelli, F., and Sgura, A. (2018). Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT). Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020606"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.5858\/arpa.2016-0202-RA","article-title":"Common Fluorescence In Situ Hybridization Applications in Cytology","volume":"140","author":"Savic","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cll.2022.09.020","article-title":"Utility of Fluorescence In Situ Hybridization in Clinical and Research Applications","volume":"42","author":"Vance","year":"2022","journal-title":"Clin. Lab. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O","article-title":"Telomere length measurements using digital fluorescence microscopy","volume":"36","author":"Poon","year":"1999","journal-title":"Cytometry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.0407512102","article-title":"c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus","volume":"102","author":"Louis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1078\/0171-9335-00430","article-title":"Cell cycle-dependent 3D distribution of telomeres and telomere repeat-binding factor 2 (TRF2) in HaCaT and HaCaT-myc cells","volume":"83","author":"Ermler","year":"2004","journal-title":"Eur. J. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2014-08-594176","article-title":"LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates","volume":"125","author":"Lajoie","year":"2015","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0092-8674(00)80932-0","article-title":"TRF2 protects human telomeres from end-to-end fusions","volume":"92","author":"Smogorzewska","year":"1998","journal-title":"Cell"},{"key":"ref_74","first-page":"647","article-title":"High mobility group protein I(Y): A candidate architectural protein for chromosomal rearrangements in prostate cancer cells","volume":"62","author":"Takaha","year":"2002","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1101\/gad.1067003","article-title":"Genomic targets of the human c-Myc protein","volume":"17","author":"Fernandez","year":"2003","journal-title":"Genes Dev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.aanat.2010.07.006","article-title":"3D structural and functional characterization of the transition from Hodgkin to Reed-Sternberg cells","volume":"192","author":"Knecht","year":"2010","journal-title":"Ann. Anat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/labinvest.2017.33","article-title":"Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells","volume":"97","author":"Knecht","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-6655-4_6","article-title":"The Use of 3D Telomere FISH for the Characterization of the Nuclear Architecture in EBV-Positive Hodgkin\u2019s Lymphoma","volume":"1532","author":"Knecht","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1158\/1078-0432.CCR-12-0087","article-title":"Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups","volume":"18","author":"Gadji","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1593\/neo.91752","article-title":"Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients","volume":"12","author":"Gadji","year":"2010","journal-title":"Neoplasia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-387688-1.00004-1","article-title":"Nuclear remodeling as a mechanism for genomic instability in cancer","volume":"112","author":"Gadji","year":"2011","journal-title":"Adv. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Yu, P.L.I., La, L.S., Asbaghi, Y., Sisdelli, L., Tammur, P., Tamm, A., Punab, M., Klewes, L., and Louis, S. (2021). Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13081969"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/thy.2013.0118","article-title":"Three-dimensional telomere dynamics in follicular thyroid cancer","volume":"24","author":"Wark","year":"2014","journal-title":"Thyroid"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Sisdelli, L., Cordioli, M.I.V., Vaisman, F., Caria, P., Mai, S., and Cerutti, J.M. (2020). Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations. Cancers, 12.","DOI":"10.3390\/cancers12113146"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1002\/jcp.27321","article-title":"Characterizing the three-dimensional organization of telomeres in papillary thyroid carcinoma cells","volume":"234","author":"Caria","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Drachenberg, D., Awe, J.A., Rangel Pozzo, A., Saranchuk, J., and Mai, S. (2019). Advancing Risk Assessment of Intermediate Risk Prostate Cancer Patients. Cancers, 11.","DOI":"10.3390\/cancers11060855"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/ijc.34667","article-title":"Three-dimensional nuclear architecture distinguishes thyroid cancer histotypes","volume":"153","author":"Dettori","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molcel.2007.10.005","article-title":"Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres","volume":"28","author":"Xu","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gonsalves, W.I., and Rajkumar, S.V. (2022). Monoclonal Gammopathy of Undetermined Significance. Ann. Intern. Med., 175.","DOI":"10.7326\/AITC202212200"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/leu.2011.126","article-title":"Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","volume":"39","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Davies","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_105","unstructured":"Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, and Chinese Myeloma Committee-Chinese Hematology Association (2025). Expert consensus on the comprehensive management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in China (2025). Chin. J. Hematol., 46, 198\u2013208."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1200\/EDBK_238527","article-title":"Induction Therapy for Newly Diagnosed Multiple Myeloma","volume":"39","author":"Paul","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zhuang, Z., Tian, Y., Shi, L., Zou, D., Feng, R., Tian, W.W., Yu, H., Dong, F., Liao, A., and Ma, Y. (2023). Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: A real-world multi-centered study in China. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1028571"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ding, H., Xu, J., Lin, Z., Huang, J., Wang, F., Yang, Y., Cui, Y., Luo, H., Gao, Y., and Zhai, X. (2021). Minimal residual disease in multiple myeloma: Current status. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00328-2"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kostopoulos, I.V., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Tsitsilonis, O.E., and Terpos, E. (2020). Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00860"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ng.993","article-title":"Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk","volume":"44","author":"Broderick","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2012.09047.x","article-title":"Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium","volume":"157","author":"Campa","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ng.2733","article-title":"Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk","volume":"45","author":"Chubb","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2011.352","article-title":"Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: A case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium","volume":"26","author":"Martino","year":"2012","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2141.2012.09244.x","article-title":"Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma","volume":"158","author":"Martino","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ng.2583","article-title":"The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma","volume":"45","author":"Weinhold","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"10203","DOI":"10.1038\/ncomms10203","article-title":"Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients","volume":"6","author":"Ziv","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","article-title":"Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma","volume":"23","author":"Manier","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_121","first-page":"1085","article-title":"Mutational signatures and mutable motifs in cancer genomes","volume":"19","author":"Rogozin","year":"2018","journal-title":"Brief. Bioinform."},{"key":"ref_122","first-page":"2109","article-title":"Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma","volume":"9","author":"Flactif","year":"1995","journal-title":"Leukemia"},{"key":"ref_123","first-page":"3854","article-title":"Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization","volume":"55","author":"Drach","year":"1995","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/gcc.2870070305","article-title":"Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in multiple myeloma","volume":"7","author":"Lee","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1034\/j.1600-0609.2003.00157.x","article-title":"Telomere shortening in patients with plasma cell disorders","volume":"71","author":"Cottliar","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1182\/blood-2002-11-3451","article-title":"Telomerase and telomere length in multiple myeloma: Correlations with disease heterogeneity, cytogenetic status, and overall survival","volume":"101","author":"Wu","year":"2003","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2119\/molmed.2010.00057","article-title":"Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"16","author":"Panero","year":"2010","journal-title":"Mol. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/cncr.10472","article-title":"Clinical significance of telomerase activity in multiple myeloma","volume":"94","author":"Shiratsuchi","year":"2002","journal-title":"Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1111\/j.1582-4934.2012.01628.x","article-title":"Expression profile of telomere-associated genes in multiple myeloma","volume":"16","author":"Catalina","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjh.14643","article-title":"Telomere length is a critical determinant for survival in multiple myeloma","volume":"178","author":"Hyatt","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1002\/ijc.29101","article-title":"Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length","volume":"136","author":"Campa","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1158\/1055-9965.EPI-14-0247","article-title":"Leukocyte telomere length in relation to pancreatic cancer risk: A prospective study","volume":"23","author":"Campa","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jcp-2023-209005","article-title":"Alternative lengthening of telomeres: Mechanism and the pathogenesis of cancer","volume":"18","author":"Mori","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/sj.onc.1205058","article-title":"Alternative lengthening of telomeres in mammalian cells","volume":"21","author":"Henson","year":"2002","journal-title":"Oncogene"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Tellez-Gabriel, M., Ory, B., Lamoureux, F., Heymann, M.F., and Heymann, D. (2016). Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122142"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Yu, P.L.I., Wang, Y., Tammur, P., Tamm, A., Punab, M., Rangel-Pozzo, A., and Mai, S. (2019). Distinct Nuclear Organization of Telomeresand Centromeres in Monoclonal Gammopathyof Undetermined Significance and Multiple Myeloma. Cells, 8.","DOI":"10.3390\/cells8070723"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-140612","article-title":"Three-Dimensional Telomere Analysis Using Teloview\u00ae Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort","volume":"136","author":"Louis","year":"2020","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kumar, S., Rajkumar, V., Jevremovic, D., Kyle, R., Mai, S., and Louis, S. (2023). P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. Hemasphere, 7.","DOI":"10.1097\/01.HS9.0000970804.07945.f9"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.4254","article-title":"Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ajh.27414","article-title":"Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma","volume":"99","author":"Kostopoulos","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/23\/1890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T05:19:56Z","timestamp":1764479996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/23\/1890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":143,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cells14231890"],"URL":"https:\/\/doi.org\/10.3390\/cells14231890","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}